COMy 2022 | The value of genomics in Waldenström’s macroglobulinemia
In this video, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of genomics in Waldenström’s macroglobulinemia (WM), highlighting the role of genomics in helping clinicians to better understand patient presentation, prognosis, and treatment response. Dr Treon also comments on the benefits of using PCR for patients with MYD88 mutation, and sequencing methods that can be used when analyzing CXCR4 mutations. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Research support, consulting and/or honoraria received from: Abbvie/Pharmacyclics, Beigene, BMS, Eli Lilly, Janssen Pharmaceuticals, X4 Pharmaceuticals. IP assigned to DFCI for MYD88, CXCR4, and IRAK and HCK and other inhibitors.
